Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

September 30, 2015

Conditions
Triple Negative Breast Cancer
Interventions
PROCEDURE

Needle core biopsies

"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."

PROCEDURE

Needle core biopsies of metastatic lesion

"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."

Trial Locations (8)

Unknown

John H. Stroger, Jr. Hospital of Cook County, Chicago

Centre Hospitalier de l'Université de Montréal -- Hotel-Dieu, Montreal

Centre Hospitalier de l'Université de Montréal- Notre-Dame, Montreal

Hôpital Royal Victoria, Montreal

Hôpital Sacré-Coeur, Montreal

Jewish General Hospital, Montreal

St-Mary's Hospital Center, Montreal

Hopital du St-Sacrement, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Exactis Innovation

OTHER

collaborator

Genome Quebec

OTHER

lead

Jewish General Hospital

OTHER

NCT01276899 - Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | Biotech Hunter | Biotech Hunter